1. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14
Absorb is authorized for sale in CE Mark and certain independently regulated
countries outside the United States. Please check the regulatory status of the
device before distribution in areas where CE Mark is not the regulation in force. For
presentation only outside the United States.
Miriam Bascones Ilundain

2. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14
Video Innovación.mp4
2

3. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14 3

4. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14 4
¿QUÉ ES INNOVAR?

5. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14 5
BIOMIMÉTICA

6. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14

7. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14

8. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14

9. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14

10. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14 10
Atul Gawande

11. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14 11

12. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14 12

13. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14
Abbott Vascular
Absorb
 Abbott Vascular ha hecho inversiones importantes en
tiempo, recursos y capital humano para liderar el campo de
la tecnología bioreabsorbible y el campo de la cardiología
intervencionista
R&D Commitment and Investment
$500 MILLION
260,000360
approximately
more than
Absorb units built, tested, and validated
invested to research, develop, and
commercialize Absorb
dedicated R&D and technical staff
Data on file at Abbott Vascular as of February 2014
13

14. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14
Abbott Vascular
Absorb
Experiencia clínica y comercial global
Clinical / Special Access
Commercial
Leading global trials by
total patient enrollment1
Available in over 60 countries
worldwide since launch in 2012
 Abbott-sponsored Absorb trials (10) = 9,709 patients
 Investigator-sponsored Absorb trials (14) = 12,894 patients
 Other bioresorbable platforms = 387 patients
1. Includes publically-disclosed in-progress and planned clinical trials for clinically active coronary bioresorbable platforms as of January 2014
Clinical trial patient data from TCT 2013 company presentations and Patel N, et al. Heart 2013:99 1236–1243. doi:10.1136/heartjnl-2012-303346
98.4%
1.6%
Absorb
Other
14

15. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14
Abbott Vascular
Absorb
 MULTI-LINK design
 Everolimus and release profile
 Benign resorption
 Radiopaque markers
 Minimal scaffold recoil
 Radial strength
 Room temperature storage and
handling
 Product shelf life
Atributos técnicos y prioridades del desarrollo
Current Generation Absorb Near-Term Investments
 Expanded size matrix
 Optimized scaffold delivery system for
improved acute performance
 Thinner scaffold struts and profile
improvements for better deliverability
 Enhanced expansion capabilities
 Expanded size matrix
Next Generation Investments
15

16. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14
Abbott Vascular
Pioneering the PCI Revolution with Absorb
Vessel Support
Time
Recoil
Radial Strength
Deliverability
Flexibility
Size Matrix
Radiopacity
Drug Delivery
Profile
Expansion
Capability
Strut Thickness
Consideraciones de próximas generaciones de dispositivos
bioreabsorbibles
 To evaluate and balance
various design
characteristics and
technical attributes
 To create a polymer-based
coronary bioresorbable
vascular scaffold that
offers DES-like
performance and
capabilities
16

17. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14
n=~599 n~965 n~5,709 n~7,609 n~8,709 n~9,709
2011 2012 2014 2014 2015 2016
ABSORB Japan
n = 400, Japan Pivotal RCT
Enrollment & Follow-Up 2 Y1 Y
ABSORB China
n = 440, China Pivotal RCT
Enrollment & Follow-Up 2 Y1 Y
ABSORB II
n = ~501, International RCT
2 Y 3 Y1 YEnrollment & Follow-Up
ABSORB EXTEND
n = 814, Registry
2 Y 3 Y1 YEnrollment & Follow-Up
ABSORB Cohort B
n = 101; FIM
1 Y 2 Y 3 Y 4 Y 5 Y
ABSORB Cohort A
n = 30; FIM
5 Y
ABSORB FIRST
n = ~2,000, International Registry
Enrollment & Follow-Up 1 Y
Each trial n reflects total patients. Data as of January 2014
*ABSORB IV trial is in the planning stage and subject to change
ABSORB III
n = 2,235, US Pivotal RCT
Enrollment & Follow-Up 1 Y 2 Y
ABSORB IV*
n = ~3,000, US RCT
UK Registry
n = 1,000, UK Registry
Enrollment & Follow-Up 1 Y
Global Clinical and Commercial Experience
Comprehensive Abbott-Sponsored Clinical Program
Total Patients Studied
17

18. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14
Global Clinical and Commercial Experience
Investigator-Sponsored Studies (ISS)
18
Data on file at Abbott Vascular; data as of February 2014
*Enrollment has not started yet
Randomized Controlled Trials (2,764 Pts)
Study Title Country S-I Design
Enrolled /
Target
Patients
Primary Endpoint
Follow
Up
(Years)
AIDA Netherlands Dr. Henriques All-comers RCT vs. XIENCE 275 / 2,194 2-Year TVF 5
TROFI II
Netherlands /
Spain / Switzerland
Dr. Serruys /
Dr. Sabaté /
Dr. Windecker
STEMI RCT vs. XIENCE 6 / 190 6-Month neo-intimal healing score 3
PROSPECT II
ABSORB
Nordics
Dr. Erlange /
Dr. Stone
RCT vs. OMT in unstable asymptomatic
patients
0 / 300* 2-Year IVUS MLA 3
PROACTIVE Belgium Dr. Barbato RCT vs. XIENCE 1 / 20 Peri-procedure platelet reactivity 1
VANISH Netherlands Dr. Knaapen RCT vs. XIENCE 20 / 60 Evolution of myocardial blood flow over time 3
Registries (10,130 Pts)
BVS EXPAND Netherlands Dr. van Geuns All-comers Registry (excl. STEMI) 238 / 300 1-Year MACE 5
ASSURE Germany Dr. Mathey All-comers Registry 180 / 180 Safety and efficacy 3
ABSORB CTO Spain Dr. Serra Feasibility in CTO 20 / 20 Safety and performance 2
PABLOS Italy Dr. Colombo Feasibililty in Bifurcations 4 / 30 Device, procedural, main, and sidebranch success 2
IT-
DISSAPEARS
Italy
Dr. Bedogni /
Dr. Petronio
MVD and Long Lesion Registry 4 / 1,000 Safety and efficacy 5
GABI-R Germany/Austria Dr. Hamm All-comers Registry 66 / 5,000 Safety and efficacy 5
REPARA Spain/Portugal Dr. Hernandez All-comers Registry 1 / 1,500 1-Year MACE 1
POLAR ACS Poland Dr. Dudek ACS Registry 100 / 100
Safety, clinical device, procedure success and in-
hospital MACE
1
France
ABSORB
France
Dr. Koning /
Dr. Le Breton
Feasibility in de novo lesions 0 / 2,000* 1-Year MACE 1

19. Absorb is authorized for sale in CE Mark and certain independently regulated countries outside the United
States. Please check the regulatory status of the device before distribution in areas where CE Mark is not the
regulation in force. For presentation only outside the United States. ©2014 Abbott. All rights reserved.
AP2939615-OUS Rev. A 03/14
“En una ocasión salí de la ciudad y a la vuelta, en un punto
en el que la tierra se elevaba y veía el mar a la izquierda y
toda la carretera por delante, de pronto sentí que estaba en
el cielo. En realidad el lugar era exactamente el mismo que
el que había pasado hacía algunos minutos, pero había
cambiado mi forma de verlo”.
Yann Martel